As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Their Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and they have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, their lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approval and commercialization. At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors. It was founded in 2009 and headquartered in Irvine, California.

Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for gastric mucous membrane protection, antihistaminic agents, ischemic improvements, antithrombotic, functional digestion, hyperlipemia cure, growth hormone, anti-peptic ulcer cure, cerebral metabolic, high blood pressure, and others. The company was founded on March 1, 2013 and is headquartered in Seoul, South Korea.

The Rural Development Administration (Korean: 농촌진흥청; Hanja: 農村振興廳, RDA) is one of an agriculture organizations in South Korea and is run under the Ministry of Agriculture, Food and Rural Affairs. The headquarters are in Wansan-gu, Jeonju.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.

Manufactures pharmaceuticals

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases. The company's approach allows them to accelerate the delivery of medicines for the benefit of all humankind. The company was founded in 2019 and is headquartered in New York, United States.

Banyu Pharmaceutical Co. Ltd. produces and distributes pharmaceutical products. It researches, develops, manufactures, sells, and imports and exports ethical drugs in Japan. Banyu Pharmaceutical was founded in 1915 and is headquartered in Tokyo, Japan.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.